What were the main drivers of Amgen's revenue growth in the reported period?

Revenue growth was primarily driven by an increase in product sales, particularly for key products like Prolia®, Sensipar®/Mimpara®, and XGEVA®. Additionally, 'Other revenues' saw a substantial increase, mainly due to milestone payments from licensing transactions and higher royalty income from products like Ibrance®.

How is Amgen managing its operating expenses and what is the impact of its transformation initiatives?

Amgen is effectively managing operating expenses through ongoing transformation and process improvement efforts, which have contributed to cost savings. These initiatives helped keep operating expenses flat for the first nine months of 2016, allowing for reinvestment in pipeline development and new product launches. The company expects further cost savings from these efforts.

What is Amgen's strategy for returning capital to shareholders?

Amgen is committed to returning capital to shareholders through a combination of cash dividends and stock repurchases. In the first nine months of 2016, the company repurchased $2.0 billion of its stock and paid $2.3 billion in dividends. A significant amount remained available under its stock repurchase program, with an additional authorization in October 2016.

Are there any significant legal or regulatory matters that investors should be aware of?

Amgen is involved in various legal proceedings, including patent litigation related to its key products like Sensipar®, AMJEVITA™, and KYPROLIS®, as well as biosimilar patent litigations. The company also faces risks related to pricing and reimbursement pressures from third-party payers and governments, which could impact profitability and sales. While the company accrues for probable liabilities, the ultimate outcomes of these matters are difficult to predict and could have a material adverse effect on its financial results.

AMGN 10-Q Quarterly Report Q3 FY2016 — Revenue, Net Income, EPS

Summary

Amgen Inc. reported solid financial performance for the third quarter and the first nine months of 2016, demonstrating revenue growth and improved profitability. Total revenues for the nine months increased by 6% to $17.0 billion, driven by a 4% rise in product sales and a significant 56% increase in other revenues, largely attributed to milestone payments and royalty income. Net income for the nine-month period rose by 13% to $5.8 billion, translating to a 14% increase in diluted Earnings Per Share (EPS) to $7.63. This growth was supported by effective cost management, with operating expenses remaining flat year-over-year due to ongoing transformation and process improvement initiatives, which are expected to yield further cost savings. The company also continued to return capital to shareholders through substantial stock repurchases and increased dividend payments, signaling confidence in its financial health and future prospects.

Financial Highlights

54 data points

Beta

Revenue

$5.81B

0.8% Gross Margin

Net Income

$2.02B

0.3% Net Margin

EPS (Diluted)

$2.68

Total Assets

$78.15B

Cash & Equivalents

$3.48B

Free Cash Flow

$2.50B

Financial Statements

Beta

Revenue	$5.81B
Cost of Revenue	$1.03B
Gross Profit	$4.49B
SG&A Expenses	$1.24B
Operating Expenses	$3.28B
Operating Income	$2.53B
Interest Expense	$325.00M
Net Income	$2.02B
EPS (Basic)	$2.70
EPS (Diluted)	$2.68
Shares Outstanding (Basic)	747.00M
Shares Outstanding (Diluted)	753.00M

Key Highlights

1Total revenues increased by 6% to $17.0 billion for the nine months ended September 30, 2016.
2Net income grew by 13% to $5.8 billion for the nine months ended September 30, 2016.
3Diluted EPS increased by 14% to $7.63 for the nine months ended September 30, 2016.
4Product sales for the nine months increased by 4% to $16.2 billion, with notable growth in Prolia®, Sensipar®/Mimpara®, and XGEVA®.
5Operating expenses remained flat for the nine months, driven by cost savings from transformation and process improvement efforts.
6The company repurchased $2.0 billion of its common stock and paid $2.3 billion in dividends during the first nine months of 2016.
7Amgen continues to invest in its pipeline, with significant R&D activities, and is preparing for new product launches, evidenced by increased SG&A investments.

AMGEN INC Quarterly Report for Q3 Ended Sep 30, 2016

Summary

Financial Highlights

Key Highlights

Frequently Asked Questions